Biotherapies developed and manufactured in France in compliance with good practices
Clinical studies based on real animal treatments
Easy to use products, delivered solely by veterinarians
Précédent
Suivant
Biotherapies developed and manufactured in France in compliance with good practices
Clinical studies based on real animal treatments
Easy to use products, delivered solely by veterinarians
Précédent
Suivant

16 – Interaction of Human Mesenchymal Stem Cells With Cells Involved in Alloantigen-Specific Immune Response Favors the Differentiation of CD4+ T-cell Subsets Expressing a regulatory/suppressive Phenotype.

Rita Maccario, Marina Podestà, Antonia Moretta, Angela Cometa, Patrizia Comoli, Daniela Montagna, Liane Daudt, Adalberto Ibatici, Giovanna Piaggio, Sarah Pozzi, Francesco Frassoni, Franco Locatelli. Haematologica. Avril 2005.

Background and objectives: Experimental evidence and preliminary clinical studies have demonstrated that human mesenchymal stem cells (MSC) have an important immune modulatory function in the setting of allogeneic hematopoietic stem cell (HSC) transplantation. We extended the evaluation of mechanisms responsible for the immune regulatory effect derived from the interaction of human MSC with cells involved in alloantigen-specific immune response in mixed lymphocyte culture (MLC).

Design and methods: Dendritic cell (DC) differentiation, T- and natural killer (NK)-lymphocyte expansion, alloantigen-specific cytotoxic activity and differentiation of CD4+ T-cell subsets co-expressing CD25 and/or CTLA4 molecules were assessed, comparing the effect observed using third-party MSC with that obtained employing MSC autologous to the MLC responder.

Results: We found that human MSC strongly inhibit alloantigen-induced DC1 differentiation, down-regulate alloantigen-induced lymphocyte expansion, especially that of CD8+ T cells and of NK lymphocytes, decrease alloantigen-specific cytotoxic capacity mediated by either cytotoxic T lymphocytes or NK cells and favor the differentiation of CD4+ T-cell subsets co-expressing CD25 and/or CTLA4. More effective suppressive activity on MLC-induced T-cell activation was observed when MSC were third-party, rather than autologous, with respect to MLC-responder cells.

Interpretation and conclusions Our results strongly suggest that MSC-mediated inhibition of alloantigen-induced DC1 differentiation and preferential activation of CD4+ CD25+ T-cell subsets with presumed regulatory activity represent important mechanisms contributing to the immunosuppressive activity of MSC. Collectively, these data provide immunological support for the use of MSC to prevent immune complications related to both HSC and solid organ transplantation and to the theory that MSC are universal suppressors of immune reactivity.

For Veterinarians only

For Veterinarians only

Ask your veterinarian for the price of a stem cell injection at his clinic.

Product Pipeline

Range Product Development & optimization Proof of Concept Pilot study Industrialisation /
Manufacturing
Pivotal study Approval Marketing Launch

CANIPREN

VBX-01
Canine osteoarthritis

CA0102
Atopic dermatitis

CA0103
Atopic dermatitis
Chronic
Inflammatory
Bowel
Disease

Range Product Development & optimization Proof of Concept Pilot study Industrialisation /
Manufacturing
Pivotal study Approval Marketing Launch

FELIPREN

FE0101
Gingivostomatitis

FE0102
Chronic kidney
failure

FE0103
Feline arthrosis

Range Product Development & optimization Proof of Concept Pilot study Industrialisation /
Manufacturing
Pivotal study Approval Marketing Launch

EQUIPREN
OMBISTEM

EQ0101
Equine arthrosis